Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings    ZBH

ZIMMER BIOMET HOLDINGS

(ZBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Sales forecast by analysts have been recently revised upwards.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 160.4.
  • Technically, the stock approaches a strong medium-term resistance at USD 155.95.
  • The company is in debt and has limited leeway for investment
  • The company's enterprise value to sales, at 5.25 times its current sales, is high.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Medical Equipment, Supplies & Distribution - NEC
1st jan.Capitalisation (M$)Investor Rating
ZIMMER BIOMET HOLDINGS-0.37%30 283
ABBOTT LABORATORIES24.59%191 805
MEDTRONIC PLC0.22%152 480
BECTON, DICKINSON AND COMPA..-13.65%68 111
HOYA CORPORATION33.11%49 894
BAXTER INTERNATIONAL INC.-9.03%38 858
ALIGN TECHNOLOGY, INC.79.22%37 950
SARTORIUS STEDIM BIOTECH98.38%33 382
DEXCOM, INC.49.82%30 698
TERUMO CORPORATION6.74%30 026
SYSMEX CORPORATION46.73%21 881
AMERISOURCEBERGEN CORPORATI..21.38%21 060
WEST PHARMACEUTICAL SERVICE..84.90%20 342
STERIS PLC27.16%16 537
BIO-RAD LABORATORIES, INC.45.53%16 074
AVANTOR, INC.50.30%15 777
More Results
Financials (USD)
Sales 2020 7 059 M - -
Net income 2020 -167 M - -
Net Debt 2020 6 769 M - -
P/E ratio 2020 -179x
Yield 2020 0,66%
Capitalization 30 283 M 30 283 M -
EV / Sales 2020 5,25x
EV / Sales 2021 4,39x
Nbr of Employees 19 900
Free-Float 66,5%
Upcoming event on ZIMMER BIOMET HOLDINGS
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes